Hydrophobic Interaction Chromatography Market size was valued at USD 1.7 billion in 2024 and is set to exceed USD 6.15 billion by 2037, expanding at over 10.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of hydrophobic interaction chromatography is evaluated at USD 1.99 billion.
The market growth is rising due to growing cases of infectious diseases, such as COVID-19, and higher development of vaccines. In nations around the world, more than thirty vaccines have been approved for general or emergency use. Since host cells can contaminate the final vaccine product during the manufacture of the viral vaccine, HIC is employed to remove the host cell protein, ensuring the purity and safety of the final vaccine formulations.
Rising cases of patent expiration are likely to boost hydrophobic interaction chromatography market. When a drug's patent expires, manufacturers may be forced to design their own purifying technique in order to make generic medications. In this regard, HIC can be viewed as a viable purification tool for medication development by manufacturers.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
10.4% |
|
Base Year Market Size (2024) |
USD 1.7 billion |
|
Forecast Year Market Size (2037) |
USD 6.15 billion |
Sample (Monoclonal Antibodies, Vaccines)
The monoclonal antibodies segment is estimated to hold 38% share of the global hydrophobic interaction chromatography market by 2037. There has been a significant increase in cases of cancer, autoimmune diseases, inflammatory disorders, and Alzheimer. All these diseases have increased the demand for monoclonal antibodies and higher approvals of mAB will drive the segment growth. For instance, in 2022, the FDA granted an emergency use authorization (EUA) for bebtelovimab, a novel monoclonal antibody for the treatment of COVID-19. Monoclonal antibodies are present in different isoforms, that have varying hydrophobic properties, HIC helps in separating and identifying these isoforms. This data generated after performing HIC can be used to assess the stability and consistency of the mAB products.
Products & Services (Resin, Columns, Buffer, Services)
Hydrophobic interaction chromatography market from the resin segment is expected to garner a significant share of around 40% in the year 2037. Continuous advancements in HIC resin technology are leading the segment’s growth. The development of improved resin has enhanced the performance characteristics. The advanced properties include better resolution, improved selectivity, enhances stability, higher binding capacities, and others.
Our in-depth analysis of the market includes the following segments:
|
Sample |
|
|
Product & Services |
|
|
End User |
|
North American Market Forecast
North America industry is predicted to dominate majority revenue share of 35% by 2037, impelled by growing cases of cancer and autoimmune diseases in the region. Growing cases of cancer and autoimmune diseases are driving the market growth. In 2022, the United States recorded around 1,918,030 new cancer cases and nearly 609,360 cancer deaths. Monoclonal antibodies are commonly utilized in cancer therapy. HIC allows for the production of high-purity mAB, which is employed in cancer therapy.
European Market Statistics
The European hydrophobic interaction chromatography market is estimated to be the second largest, registering a share of about 28% by the end of 2037. The presence of the leading biopharma companies leads to the higher discovery of therapies and results in higher demand for the HIC for better output of these drugs. Many of the world's biggest pharmaceutical companies have their base in Europe, including Novartis, Roche, Bayer, Novo Nordisk, AstraZeneca, Sanofi, GSK, and many others.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?